Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Alternative Names: SB-BCLmR-HSPC; SB-LSD3; SB-LSD4; ST-400; ZFN Bcl11a; ZFN therapeutics - Sangamo; ZFP nucleases - Sangamo; ZFP Therapeutic® haemoglobinopathy programme - Sangamo/Bioverativ

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Developer Bioverativ; Sangamo Therapeutics; University of Massachusetts Medical School
  • Class Antineoplastics; Cell therapies; Gene therapies; Stem cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Alpha 1 antitrypsin modulators; CCR5 receptor modulators; Cell replacements; Gene modulators; Gene silencing; Genetic transcription inhibitors; Haemoglobin modulators; Interleukin 2 receptor modulators; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Beta-thalassaemia; Sickle cell anaemia
  • No development reported Alpha 1-antitrypsin deficiency; Cancer; Down syndrome; HIV infections; Immunodeficiency disorders; Mucopolysaccharidosis I; Mucopolysaccharidosis II

Most Recent Events

  • 17 Nov 2017 Preclinical development in Beta-thalassaemia in USA (Parenteral) and Sickle cell anaemia in USA (Parenteral) is ongoing
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top